ETNPPL

Across TCGA pan-cancer cohorts, ETNPPL Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ETNPPL data layer compared with 27 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher ETNPPL Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ETNPPL expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

BLCA, ESCA, and UCEC are the cancer types where ETNPPL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	IV	0.018	0.600	<.001	12	view →
ESCA	DFS	Median	III,IV	0.143	0.448	.030	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUAD	DFS	Median	All	1.000	0.657	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ETNPPL–BLCA (OS)

Open the BLCA breakdown →